Latest revenue
$3.42B
as of 2025-09-30
Latest net income
$150.3M
as of 2025-09-30
Net margin
4.4%
as of 2025-09-30
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $12.74B
- Enterprise value
- $22.29B
- P/E (trailing)
- 17.5×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $202.69
- 52-wk low
- $101.00
- Beta
- —
- Shares out
- 64.2M
5-year trend
What this company does
DaVita operates one of the largest networks of outpatient kidney dialysis centers, treating patients with chronic kidney failure in the US and internationally. Dialysis patient service revenues drive nearly all of the top line — $9.6 billion of $10.0 billion year-to-date — billed primarily to Medicare and commercial insurers. The company is aggressively shrinking its share count through buybacks, repurchasing over $1.4 billion of stock this year and pushing shareholders' equity into a $572 million deficit while debt climbed past $10 billion.
Generated from DVA's filing dated 2025-10-29
Key risks
- Negative shareholders' equity of $(571.9)M vs. $121.1M at YE2024, driven by $1.46B YTD treasury buybacks against $10.18B long-term debt.
- Earnings deterioration: Q3 net income to DaVita fell 30% YoY to $150.3M; debt expense jumped to $431.7M YTD from $331.7M.
- Patient care costs grew 8.4% YTD outpacing 5.3% revenue growth, compressing operating margins; Q3 operating income declined to $505.8M from $534.9M.
Generated from DVA's filing dated 2025-10-29
Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q3 2025 2025-09-30 | $3.42B | +4.8% | $150.3M | -30.0% | 4.4% |
Q2 2025 2025-06-30 | $3.38B | +6.1% | $199.3M | -10.5% | 5.9% |
Q1 2025 2025-03-31 | $3.22B | +5.0% | $162.9M | -32.0% | 5.1% |
Q3 2024 2024-09-30 | $3.26B | +4.6% | $214.7M | -13.0% | 6.6% |
Q2 2024 2024-06-30 | $3.19B | +6.2% | $222.7M | +24.6% | 7.0% |
Q1 2024 2024-03-31 | $3.07B | — | $239.6M | — | 7.8% |
Q3 2023 2023-09-30 | $3.12B | — | $246.6M | — | 7.9% |
Q2 2023 2023-06-30 | $3.00B | — | $178.7M | — | 6.0% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Misc Health & Allied Services, NEC · SIC 8090
Your notes
Keep private notes on DVA — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$17.6M
Net activity
−$17.6M
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns DVA
Institutional value
$2.32B
Total shares held
17.1M
Distinct holders
382
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 2.8M | $425.2M | — | New |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | $335.1M | — | New |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.5M | $227.4M | — | New |
| 4 | Invesco Ltd. | 1.5M | $225.6M | — | New |
| 5 | DIMENSIONAL FUND ADVISORS LP | 1.1M | $176.0M | — | New |
| 6 | UBS Group AG | 650.5K | $100.0M | — | New |
| 7 | Bank of New York Mellon Corp | 457.5K | $70.3M | — | New |
| 8 | NORDEA INVESTMENT MANAGEMENT AB | 384.7K | $58.6M | — | New |
| 9 | JANE STREET GROUP, LLC | 305.9K | $47.0M | — | New |
| 10 | DEUTSCHE BANK AG\ | 262.2K | $40.3M | — | New |
| 11 | JPMORGAN CHASE & CO | 263.2K | $40.1M | — | New |
| 12 | WEDGE CAPITAL MANAGEMENT L L P/NC | 241.3K | $37.1M | — | New |
| 13 | TODD ASSET MANAGEMENT LLC | 222.7K | $34.2M | — | New |
| 14 | VANGUARD FIDUCIARY TRUST CO | 193.2K | $29.7M | — | New |
| 15 | Allianz Asset Management GmbH | 164.9K | $25.4M | — | New |
| 16 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 151.3K | $23.3M | — | New |
| 17 | RHUMBLINE ADVISERS | 120.6K | $18.5M | — | New |
| 18 | Legal & General Group Plc | 101.4K | $15.6M | — | New |
| 19 | Nuveen, LLC | 96.5K | $14.8M | — | New |
| 20 | Connor, Clark & Lunn Investment Management Ltd. | 82.0K | $12.6M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
Patient care costs rose 8.4% YoY to $2.33B while dialysis revenue grew only 5.1%—what's driving the margin compression and when does it reverse?
- 2
Long-term debt jumped to $10.18B and equity turned negative $572M after $1.46B buybacks; how do you justify continued repurchases at this leverage?
- 3
Debt expense surged 30% YoY to $432M for nine months—what's your weighted average rate and refinancing exposure over the next 18 months?
Refreshed when DVA files a new report · last from 2025-10-29